<DOC>
	<DOCNO>NCT02991456</DOCNO>
	<brief_summary>The purpose phase 2 study assess efficacy patient satisfaction oral rolapitant plus ondansetron vs. oral ondansetron monotherapy malignant glioma ( MG ) patient receive standard care radiation ( RT ) temozolomide ( TMZ ) therapy . This randomized phase 2 trial rolapitant plus ondansetron vs. ondansetron monotherapy prevention chemo-radiation induce nausea vomit primary MG subject receive RT concomitant multi-dose TMZ .</brief_summary>
	<brief_title>Rolapitant Antiemetic Malignant Glioma Patients Receiving Radiotherapy Temozolomide</brief_title>
	<detailed_description>All eligible subject receive plan total dose 54-60 gray ( GY ) radiation 75 mg/m2 TMZ daily total six week . Patients randomize receive one two antiemetic treatment sequence : sequence A involve administration ondansetron alone 3 week follow single dose rolapitant ( day 22 ) plus daily ondansetron 3 week sequence B involve single dose rolapitant ( day 1 ) plus daily ondansetron 3 week follow 3 week daily ondansetron alone . The study one primary endpoint : complete response ( CR ) rate . Participation study may result reduce chemo-radiation induced nausea vomiting , however , risk include common side effect rolapitant include decrease appetite , neutropenia , dizziness , dyspepsia , urinary tract infection , stomatitis , anemia .</detailed_description>
	<mesh_term>Glioma</mesh_term>
	<mesh_term>Nausea</mesh_term>
	<mesh_term>Vomiting</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>8- ( ( 1- ( 3,5-bis ( trifluoromethyl ) phenyl ) ethoxy ) methyl ) -8-phenyl-1,7-diazaspiro ( 4,5 ) decan-2-one</mesh_term>
	<mesh_term>Ondansetron</mesh_term>
	<criteria>Patients must histologicallyconfirmed , newlydiagnosed malignant glioma ( glioblastoma , gliosarcoma , anaplastic astrocytoma , anaplastic oligoastrocytoma , anaplastic pleomorphic xanthoastrocytoma , anaplastic oligodendroglioma ) schedule receive radiotherapy ( total 5460 Gy ) concomitant daily temozolomide therapy ( dose 75 mg/m2 one complete 6week cycle ) . Age ≥ 18 year Karnofsky ≥ 60 % Hematocrit &gt; 29 % , Absolute Neutrophil Count &gt; 1,000 cells/mm3 , platelet &gt; 100,000 cells/mm3 Serum creatinine &lt; 1.4 mg/dl , serum glutamic oxaloacetic transaminase ( SGOT ) bilirubin &lt; 1.5 time upper limit normal ( ULN ) Aspartate aminotransferase ( AST ) ≤ 2.5 x ULN . For subject know liver metastasis ≤ 5 x ULN , alanine aminotransferase ( ALT ) ≤ 2.5 x ULN . For subject know liver metastasis ≤ 5 x ULN For patient higher physiological level corticosteroid , must stable dose 1 week prior initiate study drug , dose escalated entry dose level , clinically possible Ability willingness give inform consent If sexually active , patient take contraceptive measure duration treatment Female patient childbearing potential must negative pregnancy test Screening Female patient childbearing potential must agree use acceptable method birth control 72 hour prior start radiation continue use study least 90 day final dose Male patient must agree use acceptable form birth control study Day 1 least 90 day final dose Comedication may interfere study result ; e.g. , immunesuppressive agent corticosteroid Comedications may interact rolapitant ( e.g . metoprolol/beta blocker , codeine , pimozide thioridazine ) review Duke Preston Robert Tisch Brain Tumor investigator pharmacist . Inability unwillingness cooperate study procedure Prophylactic medication prevention nausea vomit 24 hour prior start radiation therapy full course radiation therapy prohibit , exception study drug . Corticosteroids allow treatment cerebral swell Previous participation clinical trial involve rolapitant Any vomiting , retch , National Cancer Institute ( NCI ) Common Toxicity Criteria version 4.0 grade 24 nausea 24 hr . precede radiation chemotherapy Ongoing vomit organic etiology Radiotherapy abdomen within one week prior study Received rolapitant within 21 day prior study enrollment Prior cancer chemotherapy radiotherapy Any current treatment , medical history , uncontrolled condition , malignancy , ( e.g. , alcoholism sign alcohol abuse , seizure disorder , medical psychiatric condition ) , opinion investigator , would confound result study pose unwarranted risk administer study drug subject Patient known hypersensitivity administration rolapitant excipients Patient history severe renal hepatic impairment , severe bone marrow suppression , systemic infection Patient woman positive urine serum pregnancy test Screening , pregnant , breastfeeding , plan conceive child within project duration study treatment Patient take follow agent within last 48 hour prior start treatment study drug : 5HT3 antagonist ( ondansetron , granisetron , dolasetron , tropisetron , etc. ) . Palonosetron permit within 7 day prior administration investigational product Benzamides ( metoclopramide , alizapride , etc . ) Domperidone Cannabinoids Natural Killer ( NK ) 1 antagonist ( aprepitant ) Benzodiazepines ( lorazepam , alprazolam , etc . ) herbal medication preparation dos design ameliorate nausea emesis Patient take phenothiazine ( prochlorperazine , fluphenazine , perphenazine , thiethylperazine , chlorpromazine , etc . ) indication within last 48 hour prior start treatment study drug Patient ongoing vomiting , retch , dry heave , clinically significant nausea cause etiology , symptom within 24 hour prior start Day 1 study intervention , history anticipatory nausea vomit Patient must dose test drug blind study drug another investigational study within 30 day 5 halflives biologic activity test drug , whichever longer , time first study dose Patient participate clinical study include investigational agent ( e.g . magnesium porphyrin study )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>malignant glioma</keyword>
	<keyword>temozolomide</keyword>
	<keyword>temodar</keyword>
	<keyword>radiation</keyword>
	<keyword>emesis</keyword>
	<keyword>nausea</keyword>
	<keyword>vomit</keyword>
	<keyword>chemotherapy</keyword>
	<keyword>Affronti</keyword>
	<keyword>Peters</keyword>
	<keyword>00076418</keyword>
</DOC>